Citadel Advisors
CAPR icon

Citadel Advisors’s Capricor Therapeutics CAPR Stock Holding History

Citadel Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.1M Buy
564,100
+87,300
+18% +$2.33M ﹤0.01% 2515
2025
Q4 		$13.8M Sell
476,800
-276,100
-37% -$3.61M ﹤0.01% 2820
2025
Q3 		$5.43M Buy
752,900
+319,100
+74% +$2.35M ﹤0.01% 4219
2025
Q2 		$4.31M Buy
433,800
+321,500
+286% +$3.4M ﹤0.01% 4380
2025
Q1 		$1.07M Buy
112,300
+48,500
+76% +$673K ﹤0.01% 6822
2024
Q4 		$880K Sell
63,800
-88,100
-58% -$1.54M ﹤0.01% 7311
2024
Q3 		$2.31M Buy
151,900
+115,200
+314% +$570K ﹤0.01% 5261
2024
Q2 		$175K Buy
36,700
+13,800
+60% +$76.9K ﹤0.01% 10125
2024
Q1 		$155K Buy
22,900
+8,500
+59% +$41.1K ﹤0.01% 10716
2023
Q4 		$70.4K Sell
14,400
-9,700
-40% -$31.6K ﹤0.01% 11382
2023
Q3 		$82.4K Buy
24,100
+17,100
+244% +$96.1K ﹤0.01% 11134
2023
Q2 		$33.5K Sell
7,000
-32,600
-82% -$143K ﹤0.01% 12241
2023
Q1 		$167K Sell
39,600
-103,200
-72% -$444K ﹤0.01% 10465
2022
Q4 		$551K Sell
142,800
-500
-0.3% -$2.39K ﹤0.01% 8037
2022
Q3 		$860K Buy
143,300
+85,500
+148% +$437K ﹤0.01% 7320
2022
Q2 		$202K Sell
57,800
-16,800
-23% -$59.6K ﹤0.01% 10669
2022
Q1 		$256K Buy
74,600
+19,700
+36% +$77.7K ﹤0.01% 10949
2021
Q4 		$161K Buy
54,900
+31,200
+132% +$109K ﹤0.01% 12172
2021
Q3 		$95K Sell
23,700
-33,900
-59% -$154K ﹤0.01% 12935
2021
Q2 		$295K Sell
57,600
-18,600
-24% -$78.8K ﹤0.01% 11306
2021
Q1 		$357K Buy
76,200
+39,800
+109% +$229K ﹤0.01% 10444
2020
Q4 		$125K Sell
36,400
-17,200
-32% -$74.6K ﹤0.01% 10069
2020
Q3 		$281K Buy
53,600
+8,900
+20% +$51.9K ﹤0.01% 8235
2020
Q2 		$206K Buy
+44,700
New +$195K ﹤0.01% 8485

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's CAPR Position: Q1 2026 in Review

Citadel Advisors reduced its Capricor Therapeutics (CAPR) stake by 40% in Q1 2026, selling an estimated $9.67M and leaving 539,232 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

Citadel Advisors first reported a position in CAPR in Q3 2016 and has held it in 28 quarters since. The position peaked at $26M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Citadel Advisors held 539,232 shares of Capricor Therapeutics worth $16.4M as of Q1 2026.
  • Citadel Advisors sold 362,764 Capricor Therapeutics shares in Q1 2026, an estimated $9.67M.
  • Capricor Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2579 holding.
  • Citadel Advisors first reported a position in Capricor Therapeutics in Q3 2016 and has held it in 28 quarters since.
  • Citadel Advisors's Capricor Therapeutics position peaked at $26M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.